Search results for "T cell"

showing 10 items of 2228 documents

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

2019

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8(+) T cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsImmunologytype i interferonlcsh:RC254-282Proinflammatory cytokinetlr7 ligand03 medical and health sciences0302 clinical medicineImmune systemInterferonmedicineImmunology and AllergyCytotoxic T cellOriginal ResearchToll-like receptorcancer immunotherapybusiness.industryTLR7Acquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinesslcsh:RC581-607CD8medicine.drugOncoImmunology
researchProduct

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo

2018

Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsmedicine.medical_treatmentImmunologyBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyAntigenmedicineImmunology and AllergyCytotoxic T cellneoepitopescancer immunotherapycd8+ t cell cytotoxicityT-cell receptorImmunotherapyTumor-Derivedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointt cell priming030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607CD8OncoImmunology
researchProduct

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

2017

γδ T cells usually infiltrate many different types of cancer, but it is unclear whether they inhibit or promote tumor progression. Moreover, properties of tumor-infiltrating γδ T cells and those in the corresponding normal tissue remain largely unknown. Here we have studied features of γδ T cells in colorectal cancer, normal colon tissue and peripheral blood, and correlated their levels with clinicopathologic hallmarks. Flow cytometry and transcriptome analyses showed that the tumor comprised a highly variable rate of TILs (5–90%) and 4% γδ T cells on average, with the majority expressing Vδ1. Most Vδ1 and Vδ2 T cells showed a predominant effector memory phenotype and had reduced production…

0301 basic medicinelcsh:Immunologic diseases. Allergycolon cancer; DFS; IFN-g; TILs; gd T cells; Immunology and Allergy; Immunology; OncologyColorectal cancerImmunologyBiologyifn-γDFStilslcsh:RC254-28203 medical and health sciencesIFN-gmedicineCytotoxic T cellImmunology and AllergyOriginal ResearchSettore MED/04 - Patologia Generaleγδ t cellsCancergd T cellTILmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologycolon cancerOncologyTumor progressionImmunologylcsh:RC581-607Oncoimmunology
researchProduct

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

2020

Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualized manufacturing process, and CD19 target antigen loss or modulation leading to resistant and relapse following CAR therapy. A potential solution for these limitations is the use of donor-derived γδT cells as a CAR backbone. γδT cells lack allogenecity and are safely used in haploidentical transplants. Moreover, γδT cells are known to mediate natural anti-tumor responses. Here, we describe a 14-da…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentImmunologyCell Culture TechniquesPriming (immunology)Mice SCIDImmunotherapy AdoptiveCD1903 medical and health sciencesMice0302 clinical medicineAntigenMice Inbred NODTransduction GeneticmedicineAnimalsHumansImmunology and Allergyimmuno oncologyB cell malignanciesOriginal ResearchLeukemiaReceptors Chimeric Antigenbiologychimeric antigen receptorChemistrygamma-delta T cellsReceptors Antigen T-Cell gamma-deltamedicine.diseaseXenograft Model Antitumor AssaysChimeric antigen receptorLeukemia030104 developmental biologyCytokinemedicine.anatomical_structureCell cultureCancer researchbiology.proteinBone marrowlcsh:RC581-607Genetic Engineering030215 immunologyFrontiers in Immunology
researchProduct

Elevated sodium leads to the increased expression of HSP60 and induces apoptosis in HUVECs

2017

Atherosclerosis is the leading cause of death in the world. We have previously shown that expression of heat shock protein 60 (HSP60) on the surface of endothelial cells is the main cause of initiating the disease as it acts as a T cell auto-antigen and can be triggered by classical atherosclerosis risk factors, such as infection (e.g. Chlamydia pneumoniae), chemical stress (smoking, oxygen radicals, drugs), physical insult (heat, shear blood flow) and inflammation (inflammatory cytokines, lipopolysaccharide, oxidized low density lipoprotein, advanced glycation end products). In the present study, we show that increasing levels of sodium chloride can also induce an increase in intracellular…

0301 basic medicinelcsh:MedicineApoptosisBlood PressureSodium Chloride030204 cardiovascular system & hematologyVascular MedicineHeat Shock ResponseEpitheliumUmbilical veinWhite Blood CellsSpectrum Analysis Techniques0302 clinical medicineAnimal CellsGlycationMedicine and Health Scienceslcsh:ScienceCellular Stress ResponsesMultidisciplinaryCell DeathT CellsFlow CytometryProtein TransportChemistryCell ProcessesSpectrophotometryPhysical SciencesHypertensionCytophotometryCellular TypesAnatomymedicine.symptomIntracellularResearch Articlemedicine.medical_specialtyImmune CellsSodiumImmunologychemistry.chemical_elementInflammationBiologyResearch and Analysis MethodsImmunophenotypingProinflammatory cytokine03 medical and health sciencesInternal medicineHeat shock proteinHuman Umbilical Vein Endothelial CellsmedicineHumansHeat shockBlood CellsSodiumlcsh:RChemical CompoundsBiology and Life SciencesEndothelial CellsEpithelial CellsChaperonin 60Cell BiologyAtherosclerosisBiological Tissue030104 developmental biologyEndocrinologyGene Expression RegulationchemistryImmunologySaltslcsh:QBiomarkersPLOS ONE
researchProduct

Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA

2017

Jay Amin Hydroxamic Acid (JAHA; N8-ferrocenylN1-hydroxy-octanediamide) is a ferrocene-containing analogue of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA). JAHA’s cytotoxic activity on MDA-MB231 triple negative breast cancer (TNBC) cells at 72 h has been previously demonstrated with an IC50 of 8.45 M. JAHA’s lethal effect was found linked to perturbations of cell cycle, mitochondrial activity, signal transduction and autophagy mechanisms. In order to glean novel insights on how MDA-MB231 breast cancer cells respond to the cytotoxic effect induced by JAHA, and to compare the biological effect with the related compound SAHA, we have employed a combination of…

0301 basic medicinemedicine.drug_classAntineoplastic AgentsTriple Negative Breast NeoplasmsBiologyHydroxamic AcidsToxicologyStructure-Activity Relationship03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCytotoxic T cellFerrous CompoundsSettore BIO/06 - Anatomia Comparata E Citologiaskin and connective tissue diseasesVorinostatTriple-negative breast cancerVorinostatDose-Response Relationship DrugHistone deacetylase inhibitorComputational BiologyGeneral MedicineTriple Negative Breast NeoplasmsCell cycleHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologyBiochemistryCell culture030220 oncology & carcinogenesisCancer researchHistone deacetylaseJAHA Comet assay MDA-MB231 Histone Deacetylase InhibitorsDrug Screening Assays Antitumormedicine.drug
researchProduct

Prospecting for cytotoxic and antiprotozoal 4-aryl-4H-chromenes and 10-aryldihydropyrano[2,3-f]chromenes.

2018

Different studies reported that genetic predisposition or metabolic dysfunction are the risk factors for cancer. Infectious parasitic diseases were listed among factors that predispose to cancer. Because of the resemblance between the life cycle of cancer cells and some parasites, this study aimed to prepare pyran derivatives with cytotoxic and antiprotozoal potencies. Therefore, 7 chromenes, 10 pyranocoumarins, and an unexpected intermediate were obtained from a multi-reagent one-pot reaction. These compounds were evaluated for their cytotoxicity on sensitive and resistant leukemia cancer cells lines and against two protozoan parasites, namely Trypanosoma cruzi and Leishmania amazonensis a…

0301 basic medicinemedicine.drug_classAntiparasiticTHP-1 CellsTrypanosoma cruziAntiprotozoal AgentsPharmaceutical ScienceAntineoplastic AgentsApoptosisPharmacology03 medical and health sciencesStructure-Activity RelationshipParasitic Sensitivity TestsDrug DiscoverymedicineTumor Cells CulturedCytotoxic T cellHumansBenzopyransTrypanosoma cruziCytotoxicityAmastigoteCell ProliferationLeishmaniabiologyDose-Response Relationship DrugMolecular StructureChemistryCancerCell Cycle Checkpointsbiology.organism_classificationmedicine.disease030104 developmental biologyCancer cellAntiprotozoalDrug Screening Assays AntitumorArchiv der Pharmazie
researchProduct

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38

2018

The relationship between bone and immune cells is well established both in physiological and pathological conditions. Multiple myeloma (MM) is a plasma cell malignancy characterized by an increase of number and activity of osteoclasts (OCLs) and a decrease of osteoblasts (OBs). These events are responsible for bone lesions of MM patients. OCLs support MM cells survival in vitro and in vivo. Recently, the possible role of OCLs as immunosuppressive cells in the MM BM microenvironment has been underlined. OCLs protect MM cells against T cell-mediated cytotoxicity through the expression of several molecules including programmed death-ligand (PD-L) 1, galectin (Gal) 9, CD200, and indoleamine-2,3…

0301 basic medicinemedicine.drug_classT-LymphocytesT cellImmunologyOsteoclastsPlasma cellCD38Monoclonal antibodyImmunomodulation03 medical and health sciencesImmune systemOsteogenesisOsteoclastTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyGalectinMembrane GlycoproteinsChemistryAntibodies MonoclonalOsteoblastADP-ribosyl Cyclase 1030104 developmental biologymedicine.anatomical_structureCancer researchMultiple MyelomaImmunology Letters
researchProduct

Mastocytosis - pathogenesis, clinical manifestation and treatment

2017

The term mastocytosis designates a group of rare disorders characterized by typical skin lesions, frequently associated episodes of anaphylaxis, and clinical symptoms related to the release of various mediators. Dermatologists/allergists are frequently the first to establish the diagnosis. The condition is based on clonal mast cell proliferation, usually in the skin or bone marrow and only rarely in the gastrointestinal tract or other tissues. In general, mastocytosis has a good prognosis in terms of life expectancy. Rare variants - including mast cell leukemia, aggressive mastocytosis, and the exceedingly rare mast cell sarcoma - require cytoreductive therapy. In cases associated with hema…

0301 basic medicinemedicine.medical_specialtyGastrointestinal tractbusiness.industryDermatologymedicine.diseaseMast cell leukemiaDermatologyMast cell proliferation03 medical and health sciences030104 developmental biologymedicine.anatomical_structuremedicineMast cell sarcomaHematological neoplasmAllergistsBone marrowbusinessAnaphylaxisJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct